Effects of Danzhi Jiangtang Capsule on SDF-1α, CysC and renal vascular ultrasound in patients with early diabetic nephropathy

LI Zhongnan; CHENG Lihua; ZHOU Yuanyuan; XING Yuting; XING Yanyang; DOU Demei; MA Shuhong

doi:10.16305/j.1007-1334.2018.03.011

您当前的位置：

首页 >

文章列表页 >

Effects of Danzhi Jiangtang Capsule on SDF-1α, CysC and renal vascular ultrasound in patients with early diabetic nephropathy

更新时间：2022-08-31

- Effects of Danzhi Jiangtang Capsule on SDF-1α, CysC and renal vascular ultrasound in patients with early diabetic nephropathy
- Shanghai Journal of Traditional Chinese Medicine Vol. 52, Issue 3, Pages: 43-46(2018)
- 作者机构：
  
  1. 安徽中医药大学第一附属医院内分泌科,安徽,合肥,230031
  2. 安徽中医药大学研究生院,安徽,合肥,230038
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2018.03.011
  CLC：
扫描看全文
LI Zhongnan, CHENG Lihua, ZHOU Yuanyuan, et al. Effects of Danzhi Jiangtang Capsule on SDF-1α, CysC and renal vascular ultrasound in patients with early diabetic nephropathy. [J]. Shanghai Journal of Traditional Chinese Medicine 52(3):43-46(2018)
DOI：

LI Zhongnan, CHENG Lihua, ZHOU Yuanyuan, et al. Effects of Danzhi Jiangtang Capsule on SDF-1α, CysC and renal vascular ultrasound in patients with early diabetic nephropathy. [J]. Shanghai Journal of Traditional Chinese Medicine 52(3):43-46(2018) DOI： 10.16305/j.1007-1334.2018.03.011.

摘要

目的：观察丹蛭降糖胶囊对早期糖尿病肾病(DKD)患者基质细胞衍生因子-1α(SDF-1α)、胱抑素C(CysC)及肾脏血管超声的影响。方法：将90例早期DKD患者随机分为治疗组与对照组,每组45例。对照组予常规降糖、降压药,治疗组在对照组治疗措施基础上加服丹蛭降糖胶囊。两组疗程均为3个月,观察临床疗效,比较肾脏B超血流动力学指标及相关生化指标,包括空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、尿微量白蛋白(mAlb)、尿白蛋白/肌酐比值(ACR)、血肌酐(Scr)及SDF-1α、CysC的变化情况。结果：①最终完成试验者,对照组44例,治疗组43例。②治疗组、对照组临床总有效率分别为86.0%、59.1%；组间临床疗效比较,治疗组明显优于对照组(P＜0.05)。③组间治疗后比较,FPG、2hPG及HbA1c水平差异无统计学意义(P＞0.05)。④组间治疗后比较,mAlb、ACR及Scr水平差异有统计学意义,治疗组明显低于对照组(P＜0.01)。⑤组间治疗后比较,SDF-1α、CysC水平差异有统计学意义,治疗组对指标的改善明显优于对照组(P＜0.05)。⑥组间治疗后比较,双肾Vmax水平差异无统计学意义(P＞0.05),双肾RI水平差异有统计学意义(P＜0.05)。结论：丹蛭降糖胶囊联合常规西药治疗早期糖尿病肾病的疗效满意,其可通过降低血清CysC含量,调节SDF-1α水平,对抗炎症反应,改善肾脏血流灌注,保护患者的肾功能。

Abstract

Objective:To observe the effects of Danzhi Jiangtang Capsule on stromal cell-derived factor-1α(SDF-1α), Cystatin C(CysC)and renal vascular ultrasound in patients with early diabetic nephropathy. Methods90 patients with early diabetic nephropathy were randomly divided into the treatment group and control group, 45 cases in each group. The control group was treated with conventional hypoglycemic and antihypertensive drugs, the treatment group was treated with Danzhi Jiangtang Capsule based on the treatment for the control group,with a course of 3 months. The clinical efficacy was observed. The hemodynamic indexes in renal B-ultrasound and related biochemical indexes including fasting plasma glucose (FPG), postprandial 2 h plasma glucose (2 hPG), glycosylated hemoglobin (HbA1c), urinary microalbumin (mAlb), ratio of urinary albumin and creatinine (ACR) and serum creatinine (Scr) were compared, as well as SDF-1α and CysC. Results:①Finally 44 cases in the control group and 43 cases in the treatment group completed the trial. ②The clinical total effective rates of the treatment group and control group were 86.0% and 59.1% respectively. The clinical efficacy of the treatment group was significantly better than that of the control group (P,<,0.05). ③After treatment, there were no statistically significant differences on the levels of FPG, 2hPG and HbA1c between the two groups (P,>,0.05). ④After treatment, there were statistically significant differences on the levels of mAlb, ACR and Scr between the two groups, and the levels in the treatment group were significantly lower than those in the control group (P,<,0.01). ⑤After treatment, there were statistically significant differences on the levels of SDF-1α and CysC between the two groups, and the improvement in the treatment group was significantly better than that of the control group (P,<,0.05). ⑥After treatment, there was no statistically significant difference on V,max, between the two groups (P,>,0.05). There was statistically significant difference on RI between the two groups (P,<,0.05). Conclusion:Danzhi Jiangtang Capsule combined with routine western medicine shows good efficacy in the treatment of early diabetic nephropathy. It can reduce the serum CysC level, regulate the SDF-1α level, resist the inflammatory reaction, improve the renal perfusion and protect the renal function of patients.

关键词

糖尿病肾病肾消丹蛭降糖胶囊炎症修复肾功能保护肾血管病变

Keywords

diabetic nephropathyrenal diabetesDanzhi Jiangtang Capsuleinflammation repairrenal function protectionrenal vascular lesions

references

Views

202

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Yucan Granules improving podocyte damage and treating diabetic nephropathy

Research progress in monomers of traditional Chinese herbal medicine targeting PI3K/Akt/mTOR signaling pathway to prevent and treat diabetic nephropathy

Research on activating SIRT3 protein by marein to delay fibrosis damage induced by high glucose and palmitic acid in HBZY⁃1 cells

Research progress on Chinese medicine in prevention and treatment of diabetic nephropathy by interfering with NF⁃κB related signaling pathways

Cao Shili’s clinical experience in treating osteodynia of diabetic nephropathy

Related Author

No data

Related Institution

Department of Nephrology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Shanghai Key Laboratory of Traditional Chinese Clinical Medicine

Key Laboratory of Liver and Kidney Diseases， Ministry of Education

TCM Institute of Kidney Disease， Shanghai University of Traditional Chinese Medicine

Nephrology Department， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰